ELDN — Eledon Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1404281 ·
Last close
$3.89
Market Cap
$300.26M
52W High
$4.20
52W Low
$2.42
ADV30
1,537,295
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -21,181,000 | -39,025,000 | 146,667,000 | 6,152,000 | 101,903,000 |
| Dec 2025 | 0 | — | -21,484,000 | -10,447,000 | 169,009,000 | 22,808,000 | 87,924,000 |
| Sep 2025 | 0 | — | -19,070,000 | -17,459,000 | 129,857,000 | 3,669,000 | 94,497,000 |
| Jun 2025 | 0 | — | -24,733,000 | -11,216,000 | 144,909,000 | 5,741,000 | 94,575,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-62,341,000
Investing CF
$10,793,000
Financing CF
$53,807,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.74
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-401,203,000
Inventory
—
Receivables
$514,000
ST Investments
$110,528,000
EBIT TTM
$-83,251,000
Pretax Income TTM
$-45,582,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -83,251,000 | -45,617,000 | 169,009,000 | 87,924,000 | — | -62,341,000 |
| Dec 2024 | 0 | -70,577,000 | -36,184,000 | 177,405,000 | 114,959,000 | — | -47,271,000 |
| Dec 2023 | 0 | -43,000,000 | -116,537,000 | 89,066,000 | 81,858,000 | — | -39,527,000 |
| Dec 2022 | 0 | -39,780,000 | -87,966,000 | 92,793,000 | 8,610,000 | — | -28,424,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.72
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMRN | AMARIN CORP PLC\UK | $299.86M | $14.30 | — |
| ACIU | AC Immune SA | $298.20M | $2.93 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $312.90M | $5.49 | — |
| SLN | Silence Therapeutics plc | $313.64M | $6.64 | — |
| MGNX | MACROGENICS INC | $284.13M | $4.47 | — |
News headlines (Yahoo Finance, 1h cache)
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
2026-05-20 20:05 · Yahoo
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 20:05 · Yahoo
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
2026-05-01 18:00 · Yahoo
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
2026-04-30 12:15 · Yahoo
Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money
2026-04-20 14:14 · Yahoo
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
2026-04-20 11:37 · Yahoo
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
2026-03-19 21:10 · Yahoo
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
2026-03-16 11:00 · Yahoo
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference
2026-03-15 18:31 · Yahoo
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
2026-03-10 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.